

10802440

FORM PTO-1449/A and B (Modified 05 18 2005)		APPLICATION NO.: 10/802,440	ATTY. DOCKET NO.: V0139.70060US01
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		FILING DATE: March 17, 2004	CONFIRMATION NO.: 4035
		APPLICANT: Martha K. Newell	
Sheet 1 of 7	GROUP ART UNIT: 1644		EXAMINER: Not Yet Assigned Vander Kest

U.S. PATENT DOCUMENTS


Examiner's Initials	Cite No.	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication or of issue of Cited Document MM-DD-YYYY
		Number	Kind Code		
RV	A1	4,724,234		Cone, Jr.	02-09-1988
	A2	4,935,450		Cone, Jr.	06-19-1990
	A3	5,556,754		Singer et al.	09-17-1996
	A4	5,585,363		Scanlon et al.	12-17-1996
	A5	6,113,946 6133946		Cavallaro et al.	10-17-2000
	A6	2003-0150022	A1	Martha et al.	08-07-2003
	A7	2004/00054291	A1	Rogers et al.	01-08-2004
	A8	2005/0074882	A1	Newell	04-07-2005
	A9	2005/0158333	A1	Newell	07-02-2005

FOREIGN PATENT DOCUMENTS

Examiner's Initials	Cite No.	Foreign Patent Document			Name of Patentee or Applicant of Cited Document (not necessary)	Date of Publication of Cited Document MM-DD-YYYY	Translation (Y/N)
		Office/ Country	Number	Kind Code			
RV	*B1	WO	98/02579	A1	Emory University	01-22-1998	
	*B2	WO	98/31396	A1	Duke University et al.	07-23-1998	
	*B3	WO	98/45313	A1	Amylin Pharmaceuticals, Inc.	10-15-1998	
	*B4	WO	98/45438	A1	Beth Israel Deaconess Medical Center	10-15-1998	
	B5	WO	99/53953		University of Vermont	10/28/1999	
	*B6	WO	00/47617	A1	Lexicon Genetics, Inc.	08-17-2000	
	B7	WO	00/78941	A2	University of Vermont and State Agricultural College	12-28-2000	
	B5	WO	03/031643	A2	Newell et al.	04/17/2003	

OTHER ART — NON PATENT LITERATURE DOCUMENTS

Examiner's Initials	Cite No	Include name of the author (in CAPITAL LETTERS) title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, relevant page(s), volume-issue number(s), publisher, city and/or country where published.	Translation (Y/N)
RV	C1	AGRAWAL, S. et al. "Antisense therapeutics: is it as simple as complementary base recognition?" <i>Molecular Med. Today</i> , Vol. 6. pp: 72-81, 2000	
	*C2	ARSENIJEVIC et al., Disruption of the uncoupling protein-2 gene in mice reveals a role in immunity and reactive oxygen species production. <i>Nat Genet.</i> 2000 Dec;26(4):435-9.	
	*C3	ASOH et al., Expression of the apoptosis-mediator Fas is enhanced by dysfunctional mitochondria. <i>J Biochem (Tokyo)</i> . 1996 Sep;120(3):600-7.	
	*C4	BABU et al., Genetic control of multisystem autoimmune disease in encephalomyocarditis virus infected BALB/cCUM and BALB/cBYJ mice. <i>Curr Top Microbiol Immunol.</i> 1985;122:154-61.	
	*C5	BACH et al., Insulin-dependent diabetes mellitus as an autoimmune disease. <i>Endocr Rev.</i> 1994 Aug;15(4):516-42.	

EXAMINER: 	DATE CONSIDERED: 3/20/2006
---	----------------------------